Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement
Key facts
- Who runs it
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 1,000 people, planned
- Started
- 1 Jan 2022
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- TAVR Aspirin and clopidogrel
- Record updated
- 5 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age ≥18 years at the time of transcatheter aortic valve replacement (TAVR). Diagnosis of severe aortic stenosis based on current guideline-recommended echocardiographic criteria
- Undergoing transcatheter aortic valve replacement (TAVR) as part of routine clinical care
- Availability of baseline electrocardiographic assessment, including ambulatory electrocardiographic monitoring for evaluation of premature ventricular contraction (PVC) burden
- Completion of post-procedural rhythm follow-up, including ambulatory electrocardiographic monitoring at 12 months after TAVR
- Ability to provide informed consent or availability of legally authorized consent, as required by the institutional review board
Who cannot take part
- Presence of a permanent pacemaker or implantable cardioverter-defibrillator prior to TAVR
- Receipt of catheter ablation for atrial or ventricular arrhythmias before TAVR or during the follow-up period
- Absence of premature ventricular contractions at baseline (PVC burden = 0), as PVC response cannot be meaningfully assessed in this population
- Death occurring during the index hospitalization or before completion of rhythm follow-up
- Inability to complete scheduled electrocardiographic or ambulatory rhythm assessments during follow-up
- Missing or incomplete key electrocardiographic, echocardiographic, or follow-up data required for outcome assessment
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The TAVR-ELECTRO Registry (Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement) is a single-center, observational cohort study designed to systematically evaluate the occurrence, temporal evolution, and determinants of cardiac arrhythmias following transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis.
Read full original descriptionShow less
This registry retrospectively enrolls consecutive patients undergoing TAVR at Fuwai Hospital, Chinese Academy of Medical Sciences, and collects comprehensive clinical, echocardiographic, electrocardiographic, and procedural data. Particular emphasis is placed on post-procedural electrophysiological outcomes, including ventricular arrhythmias, atrial arrhythmias, and conduction disturbances. Serial rhythm assessments using standard electrocardiography and ambulatory electrocardiographic monitoring are performed during follow-up to characterize arrhythmic burden and its dynamic changes over time.
The primary objective of the TAVR-ELECTRO Registry is to identify clinical, haemodynamic, and procedural factors associated with post-TAVR arrhythmic outcomes and recovery patterns, thereby improving the understanding of electrophysiological remodeling after TAVR and informing post-procedural risk stratification and management strategies.
Treatments tested
- TAVR Aspirin and clopidogrel
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 February 2026